The combination group showed higher PSA responsiveness (33% vs 0%) and longer time to tumor progression in the observation of patient clinical outcomes (median PFS 39w vs 12w; HR=0.32), which was consistent with the findings obtained in previous studies (115), in which Sipuleucel-T combined with Ra-223 produced a more significant benefit in patients with mCRPC without additional toxicity. This evidence concerns the gene KLK3 and neoplasm.